BEIJING, March 7, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO , "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2018.
· *Total sales* in the fourth quarter of 2018 increased by 33.5% in RMB terms and 27.5% in USD terms to $114.9 million from $90.1 million in the same quarter of 2017.
· *Gross profit* increased by 30.4% to $77.3 million from $59.3 million in the same quarter of 2017. *Gross margin* increased to 67.3% from 65.8% in the same quarter of 2017.
· *Income from operations* increased by 116.8% to $42.5 million from $19.6 million in the same quarter of 2017. *Operating margin* increased to 37.0% from 21.8% in the same quarter of 2017